Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Date:1/5/2011

SAN FRANCISCO, Jan. 5, 2011 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 29th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Tuesday, January 11, 2011 at 8:30 a.m. Pacific time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 12, 2011.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Nektar's oral NKTR-118 development program to treat opioid-induced constipation and its NKTR-119 development program for the treatment of pain without constipation side effects. The company has additional pain compounds in preclinical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors. NKTR-181, a novel mu-opioid analgesic molecule, is currently in IND-enabling studies and Nektar plans to begin Phase 1 clinical studies in the first part of 2011.  

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014   Ventana Medical ...  Group, today announced that its VENTANA System for ... in the European Union for routine pathology, including ... consisting of VENTANA Virtuoso software coupled with either ... HT slide scanner, provides automated digital slide creation, ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014 /PRNewswire/ ... electrophysiology (EP) mapping and ablation device market ... use ablation to treat atrial fibrillation (AF). ... primary treatment option for AF will spur ... this application, such as advanced loop diagnostic ...
(Date:8/20/2014)... , Aug. 20, 2014  Amerigen Pharmaceuticals Ltd. ... Co. Ltd., has received Chinese FDA (CFDA) approval ... mg Tablets into the China ... marketing and distribution agreement with Sinochem Jiangsu Pharmaceutical ... its US FDA approved and China CFDA certified ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2
... South Korea, Feb. 25 Dong-A PharmTech Co., ... Pharma, has initiated,a 200 patient, phase 2 proof ... udenafil, a long acting phosphodiesterase type 5 inhibitor, ... European,study is designed to investigate the safety and ...
... Enterprise Intelligence Systems to Healthcare Market, ... #1841 --,Harris Corporation (NYSE: HRS ), ... joined forces with Cancer Treatment,Services International (CTSI) ... oncology. Harris will provide advanced imaging and ...
Cached Medicine Technology:Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 2Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 3Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment 2
(Date:8/20/2014)... August 20, 2014 Biocide Systems ... on Wrench Advisors as a consultant and partner ... large accounts. , As Wrench Advisors explains on ... help your organization plan and execute programs by ... distribution channels. Our experience developing joint venture partnerships ...
(Date:8/20/2014)... TX (PRWEB) August 20, 2014 The ... Surgery (ACPS), has expanded its presence throughout Houston to ... Mann Eye Institute and Laser Center building. ACPS plastic ... natural step forward for ACPS, which has risen to ... plastic surgery practices in the state since its establishment ...
(Date:8/20/2014)... Aug. 20, 2014 (HealthDay News) -- White, straight women ... than minority, bisexual or lesbian women, a new study ... American women, aged 21 to 44, who took part ... of the National Survey of Family Growth study. ... women said they sought treatment for infertility. This ranged ...
(Date:8/20/2014)... receiving mental health services from the Veterans Health Administration ... among all areas studied. , The RAND Corporation study, ... a substance use disorder were less satisfied than other ... abuse problems also were less likely than others to ... decisions. , The findings, published in the journal ...
(Date:8/20/2014)... predict both breast cancer relapses and responses to ... The newly found marker could help doctors classify ... regimen that is more effective. The discovery was ... of Molecular and Cell Biology (IMCB), and the ... the National University of Singapore (NUS). , Despite ...
Breaking Medicine News(10 mins):Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2Health News:White Women More Likely to Seek Fertility Treatment: Report 2Health News:Survey finds veterans generally satisfied with mental health care 2Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2
... of winning a battle with cancer, as opposed to adults, ... years ago.// A recent report has explained that despite ... absolve them from the risks of long-term health problems in ... Childhood Cancer Survivor Study is a long-standing pioneer in the ...
... patients with severe psoriasis, appear to be at increased ... in the October 11 issue of JAMA.// ,Psoriasis ... percent to 3 percent of the adult population. It ... increased C-reactive protein levels, which have been linked to ...
... Kankova and colleagues from the Departments of Parasitology, Microbiology ... and GynCentrum, in the Czech Republic, women with dormant ... who are Toxoplasma negative. // ,Toxoplasma gondii ... with a universal occurrence of 20-80%. This study is ...
... for answers, but when it comes to cancer, physicians ... cancers. While certain tests can indicate the possibility of ... to monitor patients for cancer currently is not available ... University of Virginia School of Medicine are out to ...
... Parents with allergic symptoms like wheezing, asthma, hay ... to their infants too, according to a study by ... practice of avoiding skin testing for airborne allergens before ... in this high-risk group can be detected early and ...
... dengue death was reported in the capital, taking the toll ... city hospitals.// ,The total number of dengue cases in ... victim of the mosquito-borne viral disease was 25-year-old Farahan of ... Medical Science (AIIMS) here Friday and died in the early ...
Cached Medicine News:Health News:Childhood Cancer Survivors May Suffer Health Problems in Adulthood 2Health News:Psoriasis Associated With Increased Risk For Heart Attack 2Health News:Effect of parasitic infection on baby's sex 2Health News:Researchers Developing Office-Based Cancer Screening Test 2Health News:Allergy Sufferers Pass on Allergies to their Children 2Health News:Dengue Claims Yet Another Victim in Delhi 2
Manual Lensmeter....
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
... 101 is well suited for measuring ... well as conventional spectacle lenses. It ... a full 90-degree inclination, which facilitates ... used in the vertical position. The ...
Medicine Products: